Patents by Inventor Aaron Wecksler

Aaron Wecksler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180312584
    Abstract: The present application relates to variants of an anti-IL-17A/F antibody, in particular, an glycosylation variant, a charge variant, an acidic variant, a HMWS variant, a reduction-resistant cross-linked variant, as well as compositions comprising the anti-IL-17A/F antibody and variant(s) thereof, methods of making and characterizing, and method of using the compositions thereof.
    Type: Application
    Filed: December 8, 2017
    Publication date: November 1, 2018
    Applicant: Genentech, Inc.
    Inventors: GALAHAD DEPERALTA, AARON WECKSLER, MELISSA ALVAREZ
  • Publication number: 20180079807
    Abstract: The present application relates to variants of an anti-IL-17A/F antibody, in particular, an glycosylation variant, a charge variant, an acidic variant, a HMWS variant, a reduction-resistant cross-linked variant, as well as compositions comprising the anti-IL-17A/F antibody and variant(s) thereof, methods of making and characterizing, and method of using the compositions thereof.
    Type: Application
    Filed: April 28, 2017
    Publication date: March 22, 2018
    Applicant: Genentech, Inc.
    Inventors: GALAHAD DEPERALTA, AARON WECKSLER, MELISSA ALVAREZ
  • Patent number: 9096532
    Abstract: The present invention provides compounds and compositions, e.g., a series of compounds wherein a 1,5-biarylpyrazole group is conjugated to a urea group by a non-cleavable covalent chain, that are useful as dual COX-2/sEH inhibitors. The compounds disclosed herein have activity associated with the arachidonate cascade. The activity of these compounds was demonstrated using a lipopolysaccharide (LPS) induced model of pain in the rat. The compounds of the present invention demonstrated superior anti-allodynic activity as compared to the same dose of celecoxib, i.e., a COX-2 inhibitor, also as compared to the same dose of t-AUCB, i.e., a sEH inhibitor, and also as compared to the co-administered same dose of both celecoxib and t-AUCB. The dual inhibitors of the present invention demonstrate enhanced in vivo anti-allodynic activity in a nociceptive behavioral assay.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: August 4, 2015
    Assignee: The Regents of the University of California
    Inventors: Bruce D. Hammock, Sung Hee Hwang, Karen Wagner, Christophe Morisseau, Aaron Wecksler, Guodong Zhang
  • Publication number: 20140038923
    Abstract: The present invention provides compounds and compositions, e.g., a series of compounds wherein a 1,5-biarylpyrazole group is conjugated to a urea group by a non-cleavable covalent chain, that are useful as dual COX-2/sEH inhibitors. The compounds disclosed herein have activity associated with the arachidonate cascade. The activity of these compounds was demonstrated using a lipopolysaccharide (LPS) induced model of pain in the rat. The compounds of the present invention demonstrated superior anti-allodynic activity as compared to the same dose of celecoxib, i.e., a COX-2 inhibitor, also as compared to the same dose of t-AUCB, i.e., a sEH inhibitor, and also as compared to the co-administered same dose of both celecoxib and t-AUCB. The dual inhibitors of the present invention demonstrate enhanced in vivo anti-allodynic activity in a nociceptive behavioral assay.
    Type: Application
    Filed: December 12, 2011
    Publication date: February 6, 2014
    Applicant: The Regents of the University of California
    Inventors: Bruce D. Hammock, Sung Hee Hwang, Karen Wagner, Christophe Morisseau, Aaron Wecksler, Guodong Zhang